Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SINOVAC BIOTECH LTD.

(SVA)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sinovac may get Phase III trial results of COVID-19 vaccine by December, executive says

11/20/2020 | 05:58am EDT
Media tour at Chinese vaccine maker Sinovac Biotech in Beijing

JAKARTA (Reuters) - Chinese vaccine maker Sinovac Biotech could have the results of its experimental COVID-19 vaccine from late-stage clinical trials as soon as next month, an executive said on Friday.

Sinovac's CoronaVac is in large late-stage trials in Brazil, Indonesia and Turkey. Preliminary results of early to mid-stage trials showed this week that it triggered a quick immune response but lower levels of antibodies than those seen in people who have recovered from COVID-19.

"Phase III is now running quite well," Weining Meng, senior director of Sinovac, told the Global Town Hall 2020 conference held online. "I guess maybe next month we'll have data available."

The results follow news this month from Pfizer Inc and BioNTech and from Moderna, as well as from Russia, of experimental vaccines proving more than 90% effective, based on interim data from large, late-stage trials.

Brazil and Indonesia are considering CoronaVac for inoculations in the coming months.

Meng said the company's manufacturing deals with local partners, including Indonesia's PT Bio Farma, will help it lower production costs and accelerate delivery once its vaccine gets regulatory approval.

(Reporting by Stanley Widianto; Editing by Clarence Fernandez)


ę Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE -1.09% 218.17 Delayed Quote.170.58%
EURO / BRAZILIAN REAL (EUR/BRL) -0.30% 6.1152 Delayed Quote.-2.39%
MODERNA, INC. -2.81% 201.59 Delayed Quote.98.54%
PFIZER, INC. -0.10% 39.59 Delayed Quote.7.66%
SINOVAC BIOTECH LTD. -0.31% 6.47 Delayed Quote.0.00%
US DOLLAR / RUSSIAN ROUBLE (USD/RUB) 0.30% 72.2403 Delayed Quote.-2.32%
US DOLLAR / TURKISH LIRA (USD/TRY) 1.02% 8.5463 Delayed Quote.12.87%
All news about SINOVAC BIOTECH LTD.
06/14SINOVAC BIOTECHá : Brazil's Bolsonaro asks Pfizer to speed up COVID vaccine deli..
RE
06/09China to study using CanSinoBIO COVID shots as a booster
RE
06/08SINOVAC BIOTECHá : Pfizer/BioNtech COVID-19 vaccines prove highly effective in U..
RE
06/07ASTRAZENECAá : Thailand starts long awaited COVID-19 vaccination drive
RE
06/04SINOVAC BIOTECHá : WHO warns of 'failure' unless rich countries speed up vaccine..
RE
06/04SINOVAC BIOTECHá : WHO urges countries to follow U.S., give vaccine doses to fil..
RE
06/02ASTRAZENECAá : commits to 1.8 million Thai vaccine doses amid supply anxiety
RE
06/02SINOVAC BIOTECHá : COVID-19 Vaccine Wins World Health Organization Approval for ..
MT
06/02SINOVAC BIOTECHá : World Health Organization Authorizes SINOVAC's CoronaVac« for..
BU
06/02MARKET CHATTER : GAVI in Talks With Sinovac Biotech to Expand COVID-19 Vaccine S..
MT
More news
Financials (USD)
Sales 2020 511 M - -
Net income 2020 110 M - -
Net cash 2020 1 040 M - -
P/E ratio 2020 6,66x
Yield 2020 -
Capitalization 642 M 642 M -
EV / Sales 2019 1,86x
EV / Sales 2020 -0,78x
Nbr of Employees 1 959
Free-Float 33,1%
Chart SINOVAC BIOTECH LTD.
Duration : Period :
Sinovac Biotech Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
NameTitle
Wei Dong Yin Chairman, President, CEO, Secretary & MD
Nan Wang CFO & Vice President-Business Development
Qiang Gao Chief Operating Officer & Vice President
Yuk Lam Lo Independent Director
Jian Li Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
SINOVAC BIOTECH LTD.0.00%642
CSL LIMITED6.55%104 196
WUXI BIOLOGICS (CAYMAN) INC.17.70%67 865
BIOGEN INC.65.87%61 146
SAMSUNG BIOLOGICS CO.,LTD.1.94%50 495
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.24.87%48 339